Clinical Trial Update: Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment [Phase 3]

View source ↗

Summary

Phase 3 trial update on ADS-5102 for walking impairment in multiple sclerosis; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Walking Impairment

Drugs mentioned

• ADS-5102 (amantadine)

Snippet

Sponsor: Adamas Pharmaceuticals, Inc. | Conditions: Walking Impairment, Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2021-12-21